Prehospital Abciximab in ST-Segment Elevation Myocardial Infarction
نویسندگان
چکیده
منابع مشابه
Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study.
BACKGROUND The value of prehospital initiation of glycoprotein IIb/IIIa inhibitors remains a controversial issue. We sought to investigate whether in-ambulance initiation of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) improves ST-segment elevation resolution (STR) after primary percutaneous coronary intervention (PCI). METHODS AND RESULTS MISTRAL (Myocardial ...
متن کاملPrehospital ticagrelor in ST-segment elevation myocardial infarction.
BACKGROUND The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown. METHODS We conducted an inte...
متن کاملPrehospital thrombolytic therapy for ST-segment elevation myocardial infarction.
The results of the ER-TIMI (Thrombolysis in Myocardial Infarction) 19 trial (1) provide yet another building block in the case for prehospital administration of thrombolytic agents to patients presenting with acute ST-segment elevation myocardial infarction (MI). These results reflect as accurately as possible the contemporary impact on time to administration (32-min decrease), and they come at...
متن کاملST-Segment Elevation in Acute Myocardial Infarction
Four hundred and four patients who were admitted to the hospital with their first myocardial infarction within 24 hours of the onset of symptoms were studied. In 315 patients the ECG findings in 12 standards leads (I, II, aVF, aVR, aVL, V,-V6) showed the infarction to be in the anterior wall, the inferior wall, or in multiple areas. The patients in each of these three categories were further su...
متن کاملAnticoagulation for ST-segment elevation myocardial infarction.
Adjunctive anticoagulant therapy reduces the risk of recurrent infarction and death in patients with STsegment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy.1–5 Unfractionated heparin (UFH), the first anticoagulant evaluated for this indication,1 continues to be used because of its predominantly nonrenal clearance, short half-life, reversibility, and the familiarity of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation: Cardiovascular Interventions
سال: 2012
ISSN: 1941-7640,1941-7632
DOI: 10.1161/circinterventions.111.961425